长链非编码RNA AP000695.2作为胃癌的一种新型预后生物标志物

Long Noncoding RNA AP000695.2 as a Novel Prognostic Biomarker for Gastric Cancer.

作者信息

Cheng Yun, Yi Xiaoqing, Fu Shuang, Cheng Junchi, Li Wei, Xu Hongliang

机构信息

Department of Anesthesiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022 Hangzhou, Zhejiang, China.

Department of Intensive Care Unit, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, 310022 Hangzhou, Zhejiang, China.

出版信息

Discov Med. 2023 Feb 1;35(174):28-35. doi: 10.24976/Discov.Med.202335174.4.

DOI:10.24976/Discov.Med.202335174.4

PMID:37024439

Abstract

BACKGROUND

Long non-coding RNA (lncRNA) AP000695.2 (ENSG00000248538) expresses abnormally in various malignancies, what shows its role as oncogene. However, it has not been extensively studied in gastric cancer. The aim of the current study was to explore the clinical value of AP000695.2 to prognose gastric cancer.

METHODS

The cancer genome atlas (TCGA) and the gene expression profiling interactive analysis (GEPIA) online tool were used to analyze AP000695.2 expression pattern, diagnostic and prognostic role in gastric cancer. Kaplan-Meier and Cox regression analyses were used to assess survival in patients with gastric cancer. Receiver operating curve (ROC) analysis was used to assess AP000695.2 diagnostic capacity. Nomograms were created to predict overall survival (OS) and progression free survival (PFS).

RESULTS

LncRNA AP000695.2 was abnormally upregulated in 19 types of malignancy, including gastric cancer. Survival analysis indicated that high expression of AP000695.2 was associated with poor survival of gastric cancer. Multivariate Cox regression analysis verified the independent prognostic value of AP000695.2 to predict OS (HR (hazard ratio): 1.104, 95% CI (confidence interval): 1.035-1.178, = 0.003) and PFS (HR: 1.170, 95% CI: 1.090-1.256, < 0.001). ROC analysis indicated a favorable AP000695.2 diagnostic capacity (area under the curve (AUC) = 0.890). Nomograms were also constructed for OS and PFS based on AP000695.2 expression-related risk score. Additionally, AP000695.2 was found to be positively associated with tumor-infiltrating immune cells, including classically activated (M1) macrophages, neutrophils, alternatively activated (M2) macrophages, and natural killer (NK) cells.

CONCLUSIONS

It was observed that AP000695.2 can be used as a novel biomarker to diagnose or predict survival of gastric patient.

摘要

背景

长链非编码RNA（lncRNA）AP000695.2（ENSG00000248538）在多种恶性肿瘤中表达异常，显示出其作为癌基因的作用。然而，它在胃癌中的研究尚未广泛开展。本研究的目的是探讨AP000695.2对胃癌预后的临床价值。

方法

利用癌症基因组图谱（TCGA）和基因表达谱交互式分析（GEPIA）在线工具分析AP000695.2在胃癌中的表达模式、诊断和预后作用。采用Kaplan-Meier法和Cox回归分析评估胃癌患者的生存率。采用受试者工作特征曲线（ROC）分析评估AP000695.2的诊断能力。绘制列线图以预测总生存期（OS）和无进展生存期（PFS）。

结果

lncRNA AP000695.2在包括胃癌在内的19种恶性肿瘤中异常上调。生存分析表明，AP000695.2的高表达与胃癌患者的不良生存相关。多变量Cox回归分析证实了AP000695.2对预测OS（风险比（HR）：1.104，95%置信区间（CI）：1.035-1.178，P = 0.003）和PFS（HR：1.170，95%CI：1.090-1.256，P < 0.001）的独立预后价值。ROC分析表明AP000695.2具有良好的诊断能力（曲线下面积（AUC） = 0.890）。还基于AP000695.2表达相关风险评分构建了OS和PFS的列线图。此外，发现AP000695.2与肿瘤浸润免疫细胞呈正相关，包括经典活化（M1）巨噬细胞、中性粒细胞、交替活化（M2）巨噬细胞和自然杀伤（NK）细胞。